The CAR-T cell therapy merry-go-round continues apace…

In this latest company expert interview and discussion, we explore the various challenges and poignant issues around the findings from BELINDA trial and the myriad of trial design aspects presented in the late breaking abstracts at ASH today.

There’s a lot of subtleties and nuances to think about, so who better than the Novartis clinical lead to hear what they thought about their own trial results?

BSB subscribers can read up on our ongoing commentary and analysis from the ASH annual meeting – you can either log-in or click to access the back story behind the latest innovations.

This content is restricted to subscribers

Posted by